S

Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506

Watchlist Manager
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Watchlist
Price: 191.58 CNY 0.32%
Market Cap: 76.8B CNY
Have any thoughts about
Sichuan Biokin Pharmaceutical Co Ltd?
Write Note

Sichuan Biokin Pharmaceutical Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sichuan Biokin Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cost of Revenue
-ÂĄ242.3m
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cost of Revenue
-ÂĄ1B
CAGR 3-Years
-9%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cost of Revenue
-ÂĄ6.1B
CAGR 3-Years
-17%
CAGR 5-Years
-14%
CAGR 10-Years
-24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cost of Revenue
-ÂĄ3.9B
CAGR 3-Years
0%
CAGR 5-Years
-5%
CAGR 10-Years
-11%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cost of Revenue
-ÂĄ28.8B
CAGR 3-Years
-2%
CAGR 5-Years
-7%
CAGR 10-Years
-9%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Cost of Revenue
-ÂĄ1.2B
CAGR 3-Years
-22%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
No Stocks Found

Sichuan Biokin Pharmaceutical Co Ltd
Glance View

Market Cap
76.8B CNY
Industry
Pharmaceuticals

Sichuan Biokin Pharmaceutical Co Ltd, nestled in the thriving economic landscape of China, is a dynamic force in the pharmaceutical industry. The company has carved a niche for itself by specializing in the production and commercialization of generic and proprietary drugs. Founded on the principles of innovation and accessibility, Biokin has dedicated its resources to the development of a wide range of pharmacological solutions that address both chronic and acute health conditions. Its state-of-the-art manufacturing facilities are complemented by rigorous research and development wings, where scientists and pharmacists collaborate meticulously to forge products that meet the stringent standards of efficacy and safety. At the heart of Sichuan Biokin's business model lies a commitment to affordability and quality, a combination that has enabled it to secure a significant share of the domestic pharmaceutical market. The company capitalizes on the economies of scale, leveraging its expansive production capabilities to reduce costs and enhance profit margins. By strategically aligning with healthcare providers and distributors, Biokin ensures its products efficiently reach hospitals, clinics, and pharmacies across the nation. This extensive distribution network not only enhances accessibility for patients but also cements Biokin’s reputation as a reliable pharmaceutical partner. Meanwhile, its growing portfolio of consumer healthcare products, alongside ongoing investments in biosimilars and more complex drug formulations, positions Biokin to thrive in the ever-evolving global healthcare arena.

Intrinsic Value
48.32 CNY
Overvaluation 75%
Intrinsic Value
Price
S

See Also

What is Sichuan Biokin Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-242.3m CNY

Based on the financial report for Dec 31, 2023, Sichuan Biokin Pharmaceutical Co Ltd's Cost of Revenue amounts to -242.3m CNY.

What is Sichuan Biokin Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-6%

Over the last year, the Cost of Revenue growth was -2%. The average annual Cost of Revenue growth rates for Sichuan Biokin Pharmaceutical Co Ltd have been -6% over the past three years .

Back to Top